IFALD in children: What's new? A narrative review

Intestinal failure-associated liver disease (IFALD) is a progressive liver disease complicating intestinal failure (IF). It is a preventable and reversible condition, but at the same time, a potential cause of liver cirrhosis and an indication to combined or non-combined liver and small bowel transplantation. The diagnostic criteria are not yet standardized, so that its prevalence varies widely in the literature. Pathophysiology seems to be multifactorial, related to different aspects of intestinal failure and not only to the long-term parenteral nutrition treatment. The survival rates of children with IF have increased, so that the main problems today are preventing complications and ensuring a good quality of life. IFALD is one of the most important factors that limit long-term survival of patients with IF. For this reason, more and more interest is developing around it and the number of published articles is increasing rapidly. The purpose of this narrative review was to focus on the main aspects of the etiology, pathophysiology, management, prevention, and treatment of IFALD, based on what has been published mainly in the last 10 years. Controversies and current research gaps will be highlighted with the aim to pave the way for new project and high-quality clinical trials.

[1]  M. Pakarinen,et al.  Histopathological liver steatosis linked with high parenteral glucose and amino acid supply in infants with short bowel syndrome , 2022, JPEN. Journal of parenteral and enteral nutrition.

[2]  A. V. Signorini,et al.  Outcomes of the First 54 Pediatric Patients on Long-Term Home Parenteral Nutrition from a Single Brazilian Center , 2022, Journal of pediatric gastroenterology and nutrition.

[3]  W. Cai,et al.  Intestinal Continuity Alleviates Pediatric Intestinal Failure-Associated Liver Disease , 2022, Frontiers in Surgery.

[4]  L. D’Antiga,et al.  Teduglutide in pediatric intestinal failure: A position statement of the Italian society of pediatric gastroenterology, hepatology and nutrition (SIGENP). , 2022, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[5]  E. Ghigo,et al.  Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis , 2022, Nutrients.

[6]  F. Suchy,et al.  Pharmacologic activation of hepatic farnesoid X receptor prevents parenteral nutrition–associated cholestasis in mice , 2021, Hepatology.

[7]  P. Wales,et al.  ASPEN definitions in pediatric intestinal failure. , 2021, JPEN. Journal of parenteral and enteral nutrition.

[8]  J. Moon,et al.  Evaluation of the fibrosis-4 index for detection of advanced fibrosis among individuals at risk for intestinal failure associated liver disease. , 2021, JPEN. Journal of parenteral and enteral nutrition.

[9]  M. Puder,et al.  Free Fatty Acid Receptors as Mediators and Therapeutic Targets in Liver Disease , 2021, Frontiers in Physiology.

[10]  P. Mohan,et al.  Twelve year outcomes of intestinal failure associated liver disease in children with short bowel syndrome: 97% transplant-free survival and 81% enteral autonomy. , 2021, JPEN. Journal of parenteral and enteral nutrition.

[11]  D. Christodoulou,et al.  New insights into intestinal failure–associated liver disease in adults: A comprehensive review of the literature , 2021, Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association.

[12]  S. Ieiri,et al.  The administration of hepatocyte growth factor prevents total parenteral nutrition-induced hepatocellular injury in a rat model , 2021, Pediatric Surgery International.

[13]  Justin K Chen,et al.  Liver Function in Pediatric Recipients: A Comparison of Intralipid and Smoflipid. , 2021, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[14]  M. Pakarinen,et al.  Prediction, identification and progression of histopathological liver disease activity in children with intestinal failure. , 2020, Journal of hepatology.

[15]  Hongyue Wang,et al.  Soybean Oil Lipid Minimization for Prevention of Intestinal Failure Associated Liver Disease in Late Preterm and Term Infants with Gastro-Intestinal Surgical Disorders. , 2020, JPEN. Journal of parenteral and enteral nutrition.

[16]  F. Mosca,et al.  Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease , 2020, Frontiers in Pediatrics.

[17]  L. D’Antiga,et al.  To Wean or Not to Wean: The Role of Autologous Reconstructive Surgery in the Natural History of Pediatric Short Bowel Syndrome on Behalf of Italian Society for Gastroenterology, Hepatology and Nutrition (SIGENP) , 2020, Nutrients.

[18]  Stuart A. Taylor,et al.  Serum Scoring and Quantitative Magnetic Resonance Imaging in Intestinal Failure-Associated Liver Disease: A Feasibility Study , 2020, Nutrients.

[19]  M. Benninga,et al.  The prevalence of liver fibrosis according to non-invasive tools in a pediatric home parenteral nutrition cohort. , 2020, Clinical nutrition.

[20]  P. Wales,et al.  Composite lipid emulsion for the infant at risk of intestinal failure associated liver disease: the Canadian perspective. , 2020, Journal of pediatric gastroenterology and nutrition.

[21]  Francine D Breckler,et al.  Pediatric Smoflipid Therapy: Patient Response and Safety Concerns. , 2020, JPEN. Journal of parenteral and enteral nutrition.

[22]  R. Sokol,et al.  Intestinal failure-associated liver disease (IFALD): insights into pathogenesis and advances in management , 2020, Hepatology International.

[23]  F. Tacke,et al.  Assessing Non-Invasive Liver Function in Patients with Intestinal Failure Receiving Total Parenteral Nutrition—Results from the Prospective PNLiver Trial , 2020, Nutrients.

[24]  C. Gillette,et al.  Mixed Oil-Based Lipid Emulsions vs Soybean Oil-Based Lipid Emulsions on Incidence and Severity of Intestinal Failure-Associated Liver Disease in a Neonatal Intensive Care Unit. , 2020, JPEN. Journal of parenteral and enteral nutrition.

[25]  W. Cai,et al.  Lipid Emulsion Use in Pediatric Patients Requiring Long-Term Parenteral Nutrition. , 2020, JPEN. Journal of parenteral and enteral nutrition.

[26]  R. Sokol,et al.  New Insights Into Intestinal Failure–Associated Liver Disease in Children , 2020, Hepatology.

[27]  M. Beylot,et al.  Effect of bile acid supplementation on endogenous lipid synthesis in patients with short bowel syndrome: A pilot study. , 2020, Clinical nutrition.

[28]  B. Naini,et al.  Something old, something new: liver injury associated with Total parenteral nutrition therapy and immune checkpoint inhibitors. , 2020, Human pathology.

[29]  D. Shores,et al.  Postoperative Feeding Guidelines Improve Outcomes in Surgical Infants. , 2019, JPEN. Journal of parenteral and enteral nutrition.

[30]  P. Mitchell,et al.  Growth in Infants and Children with Intestinal Failure Associated-Liver Disease Treated with Intravenous Fish Oil. , 2019, Journal of pediatric gastroenterology and nutrition.

[31]  A. Forbes,et al.  Home parenteral nutrition with an omega-3-fatty-acid-enriched MCT/LCT lipid emulsion in patients with chronic intestinal failure (the HOME study): study protocol for a randomized, controlled, multicenter, international clinical trial , 2019, Trials.

[32]  M. Pakarinen,et al.  Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24‐Week, Phase III Study , 2019, JPEN. Journal of parenteral and enteral nutrition.

[33]  P. Mitchell,et al.  Trends of INR and Fecal Excretion of Vitamin K During Cholestasis Reversal: Implications in the Treatment of Neonates With Intestinal Failure-Associated Liver Disease. , 2019, JPEN. Journal of parenteral and enteral nutrition.

[34]  M. Friedrich-Rust,et al.  Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography. , 2019, Nutrition.

[35]  C. Sergi,et al.  Mixed Lipid, Fish Oil, and Soybean Oil Parenteral Lipids Impact Cholestasis, Hepatic Phytosterol, and Lipid Composition , 2019, Journal of Pediatric Gastroenterology and Nutrition - JPGN.

[36]  Jennifer N. Cooper,et al.  Ultrasound Elastography as a Non-Invasive Method to Monitor Liver Disease in Children with Short Bowel Syndrome: Updated Results. , 2019, Journal of pediatric surgery.

[37]  Sam M. Han,et al.  Noninvasive assessment of liver fibrosis in pediatric intestinal failure patients using liver stiffness measurement by Vibration-Controlled Transient Elastography. , 2019, Journal of pediatric surgery.

[38]  J. Bines,et al.  Outcomes of Children with Chronic Intestinal Failure: Experience Over Two Decades at a Tertiary Paediatric Hospital. , 2019, Journal of pediatric gastroenterology and nutrition.

[39]  V. Kapoor,et al.  Lipid emulsions for parenterally fed term and late preterm infants. , 2018, The Cochrane database of systematic reviews.

[40]  V. Kapoor,et al.  Lipid emulsions for parenterally fed preterm infants. , 2018, The Cochrane database of systematic reviews.

[41]  O. Goulet,et al.  Long term outcomes of intestinal rehabilitation in children with neonatal very short bowel syndrome: Parenteral nutrition or intestinal transplantation. , 2018, Clinical nutrition.

[42]  H. Gwak,et al.  Effects of cyclic parenteral nutrition on parenteral nutrition-associated cholestasis in newborns. , 2019, Asia Pacific journal of clinical nutrition.

[43]  N. Fidler Mis,et al.  ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids. , 2018, Clinical nutrition.

[44]  A. Van Gossum,et al.  Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. , 2018, Clinical nutrition.

[45]  T. Ueno,et al.  Three-Year Prospective Follow-up of Potential Pediatric Candidate for Intestinal Transplantation. , 2018, Transplantation proceedings.

[46]  L. D’Antiga,et al.  Prevention and Treatment of Intestinal Failure-Associated Liver Disease in Children , 2018, Nutrients.

[47]  Robert H. Squires,et al.  The extent of intestinal failure-associated liver disease in patients referred for intestinal rehabilitation is associated with increased mortality: an analysis of the Pediatric Intestinal Failure Consortium database. , 2017, Journal of pediatric surgery.

[48]  R. Steiner,et al.  Intravenous Fish Oil and Pediatric Intestinal Failure–Associated Liver Disease: Changes in Plasma Phytosterols, Cytokines, and Bile Acids and Erythrocyte Fatty Acids , 2017, JPEN. Journal of parenteral and enteral nutrition.

[49]  P. Mitchell,et al.  Characterization of Fatty Acid Profiles in Infants With Intestinal Failure–Associated Liver Disease , 2018, JPEN. Journal of parenteral and enteral nutrition.

[50]  G. Gondolesi,et al.  Utility of Aminotransferase/Platelet Ratio Index to Predict Liver Fibrosis in Intestinal Failure–Associated Liver Disease in Pediatric Patients , 2017, JPEN. Journal of parenteral and enteral nutrition.

[51]  B. Feldman,et al.  Preventing the Progression of Intestinal Failure–Associated Liver Disease in Infants Using a Composite Lipid Emulsion: A Pilot Randomized Controlled Trial of SMOFlipid , 2017, JPEN. Journal of parenteral and enteral nutrition.

[52]  O. Goulet,et al.  Intravenous lipid emulsions in pediatric patients with intestinal failure , 2017, Current opinion in organ transplantation.

[53]  Takashige Ishikawa,et al.  A COMPREHENSIVE REVIEW OF THE LITERATURE ON SHEAR STRENGTH OF PUSH-OUT TESTS OF HEADED STUDS: Comprehensive and holistic analysis focusing on the type of slab, failure mode, and stud diameter , 2017 .

[54]  W. Cai,et al.  Altered systemic bile acid homeostasis contributes to liver disease in pediatric patients with intestinal failure , 2016, Scientific Reports.

[55]  P. Mitchell,et al.  Predictors of failure of fish-oil therapy for intestinal failure-associated liver disease in children. , 2016, The American journal of clinical nutrition.

[56]  C. Poisson,et al.  Outcome of home parenteral nutrition in 251 children over a 14-y period: report of a single center. , 2016, The American journal of clinical nutrition.

[57]  C. Mølgaard,et al.  ESPGHAN Committee on Nutrition Position Paper. Intravenous Lipid Emulsions and Risk of Hepatotoxicity in Infants and Children: a Systematic Review and Meta-analysis , 2016, Journal of pediatric gastroenterology and nutrition.

[58]  P. Vajro,et al.  Pediatric parenteral nutrition-associated liver disease and cholestasis: Novel advances in pathomechanisms-based prevention and treatment. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[59]  R. Kivisaari,et al.  Transient elastography and aspartate aminotransferase to platelet ratio predict liver injury in paediatric intestinal failure , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[60]  C. Sergi,et al.  Glucagon-Like Peptide 2 Improves Cholestasis in Parenteral Nutrition--Associated Liver Disease. , 2016, JPEN. Journal of parenteral and enteral nutrition.

[61]  K. McHugh,et al.  Prevalence of Gallstones Compared in Children With Different Intravenous Lipids , 2015, Journal of pediatric gastroenterology and nutrition.

[62]  P. Heikkilä,et al.  Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. , 2015, Journal of hepatology.

[63]  Y. Révillon,et al.  Assessment and outcome of children with intestinal failure referred for intestinal transplantation. , 2015, Clinical nutrition.

[64]  L. D’Antiga,et al.  Intestinal Failure–Associated Liver Disease: A Position Paper of the ESPGHAN Working Group of Intestinal Failure and Intestinal Transplantation , 2015, Journal of pediatric gastroenterology and nutrition.

[65]  K. Iyer,et al.  Intestinal Transplant Registry Report: Global Activity and Trends , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[66]  D. Seehofer,et al.  Reliable assessment of liver function using LiMAx. , 2015, The Journal of surgical research.

[67]  P. Heikkilä,et al.  Serum plant sterols, cholestanol, and cholesterol precursors associate with histological liver injury in pediatric onset intestinal failure. , 2014, The American journal of clinical nutrition.

[68]  A. Diamanti,et al.  Long-Term Outcome of Home Parenteral Nutrition in Patients With Ultra-Short Bowel Syndrome , 2014, Journal of pediatric gastroenterology and nutrition.

[69]  S. Eaton,et al.  Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. , 2014, JPEN. Journal of parenteral and enteral nutrition.

[70]  A. Perez-Atayde,et al.  Aspartate Aminotransferase to Platelet Ratio Index Correlates With Hepatic Cirrhosis but Not With Fibrosis in Pediatric Patients With Intestinal Failure , 2013, Journal of pediatric gastroenterology and nutrition.

[71]  P. Heikkilä,et al.  Persistent abnormal liver fibrosis after weaning off parenteral nutrition in pediatric intestinal failure , 2013, Hepatology.

[72]  J. Botha,et al.  Hepatic Fibrosis Persists and Progresses Despite Biochemical Improvement in Children Treated With Intravenous Fish Oil Emulsion , 2013, Journal of pediatric gastroenterology and nutrition.

[73]  B. Naini,et al.  Total parenteral nutrition therapy and liver injury: a histopathologic study with clinical correlation. , 2012, Human pathology.

[74]  P. Narula,et al.  Hepatocellular carcinoma in a child with intestinal failure-associated liver disease. , 2012, Journal of pediatric gastroenterology and nutrition.

[75]  K. Sharif,et al.  Long-term Outcomes of Isolated Liver Transplantation for Short Bowel Syndrome and Intestinal Failure–associated Liver Disease , 2012, Journal of pediatric gastroenterology and nutrition.

[76]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[77]  D. Zurakowski,et al.  Relationship between biopsy-proven parenteralnutrition-associated liver fibrosis and biochemical cholestasis in children with short bowel syndrome. , 2010, Journal of pediatric surgery.

[78]  Hau D. Le,et al.  Parenteral Fish Oil Improves Outcomes in Patients With Parenteral Nutrition-Associated Liver Injury , 2009, Annals of surgery.

[79]  P. Vajro,et al.  Isolated liver transplantation in children with intestinal failure-associated liver disease: a still-debated matter. , 2009, Journal of pediatric gastroenterology and nutrition.

[80]  M. Castro,et al.  Prevalence of life-threatening complications in pediatric patients affected by intestinal failure. , 2007, Transplantation proceedings.

[81]  S. Kocoshis,et al.  Nutritional management of infants with short bowel syndrome. , 2007, Seminars in perinatology.

[82]  P. Tsao,et al.  Ursodeoxycholic acid (UDCA) therapy in very-low-birth-weight infants with parenteral nutrition-associated cholestasis. , 2004, The Journal of pediatrics.

[83]  R. Ehrenkranz,et al.  Total Parenteral Nutrition induced Liver Pathology: An Autopsy Series of 24 Newborn Cases , 2004, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[84]  M. Fairchok,et al.  Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. , 2004, Journal of pediatric gastroenterology and nutrition.

[85]  O. Goulet,et al.  Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. , 2000, JPEN. Journal of parenteral and enteral nutrition.

[86]  R. Shamir,et al.  Parenteral Nutrition-Associated Cholestasis in Preterm Neonates: Evaluation of Ursodeoxycholic Acid Treatment , 1999, Journal of pediatric endocrinology & metabolism : JPEM.

[87]  A. Guarino,et al.  Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. , 1996, Gastroenterology.

[88]  P. Ingrand,et al.  Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? , 1994, Journal of hepatology.

[89]  K. Ishak,et al.  Total parenteral nutrition: a histopathologic analysis of the liver changes in 20 children. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.